AUA 2019: Intradetrusor Injection of Adult Muscle-Derived Cells for the Treatment of Underactive Bladder

Chicago, IL ( Dr. Diokno introduced interim data on a novel treatment for patients with underactive bladder (UAB). Detrusor underactivity is often associated with aging. Previous research indicates that 22% of men and 11% of community-dwelling women have difficulties with emptying their bladders and 66% of nursing home residents have detrusor underactivity. The aim of the presented study was to evaluate long-term efficacy and safety of adult muscle-derived cells (AMDC) for the treatment of UAB at 1, 3, 6, 12, and 24 months.

Study cohort included 20 non-neurogenic, unresponsive to treatment UAB patients with post-void residual (PVR) of 150 ml or more. Research team performed a biopsy of Quadriceps femoris muscle and sent 150+ mg of tissue to the processing lab where cells were isolated from the muscle specimen. Cell culture was performed, tested for quality, and shipped back to the site. Each subject received 30 intradetrusor injections of 0.5 mL for a total of 15 mL using a flexible cystoscope under local topical anesthesia.

According to the presenter, there were no serious adverse events related to muscle harvesting, AMDC, and injections. Data indicate improvement in UAB symptoms at the assessment time points (Table 1).

Table 1

Interim analysis of AMDC injections shows improvement trend in overall bladder function and safety. Future multi-center controlled study is needed to further investigate effects of a novel therapy for patients with UAB.

Presented by: Ananias C. Diokno, MD; Oakland University William Beaumont School of Medicine

Written by: Hanna Stambakio, BS, Clinical Research Coordinator, Division of Urology, University of Pennsylvania @AStambakio at the American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois
email news signup